Mechanism of Action
N-Type Calcium Channel Blockade
Ziconotide binds specifically and with high affinity (Kd ~0.1 nM) to the alpha1B subunit of N-type voltage-gated calcium channels (Cav2.2). N-type channels are concentrated at presynaptic terminals of C-fibers and A-delta fibers in the spinal dorsal horn. During nociceptive signaling, action potentials open N-type channels, allowing Ca2+ influx that triggers exocytosis of pain neurotransmitters (substance P, glutamate, cgrp/" class="wiki-internal-link">CGRP). Ziconotide blocks this Ca2+ influx, preventing transmitter release and interrupting pain signal transmission to ascending pathways.
Intrathecal Delivery Rationale
Systemic ziconotide is ineffective because it does not cross the blood-brain barrier, and systemic N-type channel blockade would cause cardiovascular and neural adverse effects. Intrathecal delivery concentrates the drug in CSF at the site of action (dorsal horn) while minimizing systemic exposure. The implanted pump allows continuous CSF infusion at nanogram-per-day doses that produce CSF concentrations sufficient for Cav2.2 blockade in the dorsal horn without systemic toxicity.
Opioid-Independent Analgesia
Ziconotide produces analgesia entirely independently of opioid receptors. It does not cross-react with mu, delta, or kappa opioid receptors and does not cause opioid-type side effects (respiratory depression, constipation, sedation in usual doses). This mechanism-independence means ziconotide remains effective in opioid-tolerant patients and does not exhibit tolerance with continued use, unlike opioids. It can be combined with intrathecal opioids for additive analgesia.
Research Summary
Severe Chronic Pain (Approved)
Standard of CarePivotal trials showed ziconotide produced clinically meaningful pain reduction in cancer pain, AIDS-related pain, and neuropathic pain. Visual Analog Scale of Pain Intensity (VASPI) scores improved 14-53% versus 7-18% for placebo. Efficacy is maintained long-term without tolerance. International Neuromodulation Society guidelines recommend ziconotide as a first-line intrathecal analgesic option for appropriate patients.
Cancer and Neuropathic Pain
ClinicalZiconotide is particularly valuable in cancer pain with significant neuropathic component where high-dose opioids cause intolerable side effects or hyperalgesia. In failed back surgery syndrome with radiculopathy, ziconotide provides analgesia where spinal mechanisms are dysfunctional. Long-term follow-up (>1 year) studies confirm sustained efficacy without dose escalation, a major advantage over opioid pumps.
Pain Neurobiology Research
Research ToolOmega-conotoxins including ziconotide are invaluable research tools for dissecting the role of Cav2.2 channels in pain processing, synaptic transmission, and neuronal excitability. They have revealed that N-type channels are the primary Ca2+ entry pathway for nociceptive neurotransmitter release, established target validation for Cav2.2 as a pain target, and inspired development of oral N-type channel blockers and state-dependent inhibitors.
Calculate your Ziconotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Chronic pain (IT pump) | Start 0.1 mcg/h IT; titrate by no more than 2.4 mcg/day q2-7 days | Continuous IT infusion; titrate slowly over weeks to months | IT via implanted programmable pump |
| Research (spinal cord preparation) | 0.1-100 nM in perfusion solution | Continuous perfusion during electrophysiology recording | Spinal superfusion (in vitro/in vivo) |
Ziconotide requires very slow titration to minimize CNS adverse effects. Do not use IV, IM, or epidurally, intrathecal only. Psychiatric pre-screening required (contraindicated with psychosis or history of psychosis).
Interactions
Safety Profile
Ziconotide's narrow therapeutic window and CNS side effects are its primary limitations. Common adverse effects: dizziness, nausea, confusion, abnormal gait, headache, memory impairment. Severe psychiatric adverse effects (psychosis, hallucinations, depression, suicidal ideation) occur in 3-5% of patients, psychiatric contraindications must be screened. Meningitis risk from intrathecal catheter. CK elevation (rhabdomyolysis-like) reported with high doses. Overdose causes cardiovascular and CNS toxicity requiring pump cessation. These risks require specialized pain management teams experienced with intrathecal therapy.
References
- [1]Staats PS, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA. 2004;291:63-70.
- [2]Atanassoff PG, et al. Ziconotide, a new N-type calcium channel blocker. Reg Anesth Pain Med. 2000.
- [3]Rauck RL, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006.